Dendreon Corporation Inc. (DNDN) Announces Successful Phase III Prostate Impact Study
In today’s pharmaceutical world, one needs to be fast off the mark. It is just a few hours old, but there may still be time to catch this one as investors make their choices. Prostate cancer treatment products are the next Lipitor, do your research and think about it. Dendreon Corporation, a biotechnology company, works to develop and commercialize biotechnology therapeutics that enhance cancer treatment options. The company has several products in its product development pipeline with a prostate product making very successful progress in late stage approvals. As we've stated in the past, there is a rush for larger…